Regeneron Pharmaceuticals, Inc. (REGN) said the newly updated National Institutes of Health COVID-19 Treatment Guidelines strongly recommend that REGEN-COV be used in non-hospitalized COVID-19 patients at high risk of clinical progression. Also, the NIH COVID-19 Treatments Guidelines Panel recommended that REGEN-COV use should be considered for persons with mild-to-moderate COVID-19 who are hospitalized for a reason other than COVID-19 but who otherwise meet the EUA criteria.
The company noted that the new guidelines are based in part on robust clinical data involving more than 4,500 outpatients showing that REGEN-COV significantly reduced the risk of hospitalization or death by 70% compared to placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.